Clearing the complexity: Immune complexes and their treatment in lupus nephritis

International Journal of Nephrology and Renovascular Disease

Volumn 4, Issue , 2011, Pages 17-28

  Toong, Catherine ^a   Adelstein, Stephen ^a   Phan, Tri Giang ^b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Immune complex; Nephritis; Systemic lupus erythematosus; Therapy

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; RITUXIMAB;

ANTIBODY PRODUCTION; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; B LYMPHOCYTE; DRUG DOSE REDUCTION; DRUG MEGADOSE; FEEDBACK SYSTEM; HUMAN; IMMUNOLOGICAL TOLERANCE; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE DEPLETION; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; NUCLEOSOME; PATHOGENESIS; PLASMA CELL; REVIEW;

EID: 79952944239     PISSN: None     EISSN: 11787058     Source Type: Journal    
DOI: 10.2147/IJNRD.S10233     Document Type: Review

References (103)

1. Rahman A, Isenberg DA. Mechanisms of disease: systemic lupus erythematosus. N Engl J Med. 2008;358:929-939.
2. Radic M, Marion T, Monestier M. Nucleosomes are exposed at the cell surface in apoptosis. J Immunol. 2004;172:6692-6700.
3. Biesecker G, Katz S, Koffler D. Renal localization of the membrane attack complex in systemic lupus erythematosus nephritis. J Exp Med. 1981;154:1779-1794.
4. Ortega LM, Schultz DR, Lenz O, et al. Lupus nephritis: pathologic features, epidemiology, and a guide to therapeutic decisions. Lupus. 2010;19:557-574.
5. Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65:521-530.
6. Najafi CC, Korbet SM, Lewis EJ, et al. Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. Kidney Int. 2001;59:2156-2163.
7. Borchers AT, Keen CL, Shoenfeld Y, et al. Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus. Autoimmun Rev. 2004;3:423-453.
8. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003;82:299-308.
9. Levinsky RJ, Cameron JS, Soothill JF. Serum immune complexes and disease activity in lupus nephritis. Lancet. 1977;1:564-567.
10. Mortensen ES, Rekvig OP. Nephritogenic potential of anti-DNA antibodies against necrotic nucleosomes. J Am Soc Nephrol. 2009;20: 696-704.
11. Cruchaud A, Chenais F, Fournie GJ, et al. Immune complex deposits in systemic lupus erythematosus kidney without histological or functional alterations. Eur J Clin Invest. 1975;1975:297-309.
12. Forger F, Matthias T, Oppermann M, et al. Clinical significance of anti-dsDNA antibody isotypes: IgG/IgM ratio of anti-dsDNA antibodies as a prognostic marker for lupus nephritis. Lupus. 2004;13: 36-44.
13. Amoura Z, Koutouzov S, Chabre H, et al. Antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus. Arthritis Rheum. 2000;43:76-84.
14. Bijl M, Dijstelbloem HM, Oost WW, et al. IgG subclass distribution of autoantibodies differs between renal and extra-renal relapses in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2002;41:62-67.
15. Villalta D, Romelli PB, Savina C, et al. Anti-dsDNA antibody avidity determination by a simple reliable ELISA method for SLE diagnosis and monitoring. Lupus. 2003;12:31-36.
16. Jaekel H-P, Trabandt A, Grobe N, et al. Anti-dsDNA antibody subtypes and anti-C1q antibodies: toward a more reliable diagnosis and monitoring of systemic lupus erythematosus and lupus nephritis. Lupus. 2006;15:335-345.
17. Fenton KA, Tommeras B, Marion TN, et al. Pure anti-dsDNA mAbs need chromatin structures to promote glomerular mesangial deposits in BALB/c mice. Autoimmunity. 2010;43:179-188.
18. Kohro-Kawata J, Wang P, Kawata Y, et al. Highly cationic anti- DNA antibodies in patients with lupus nephritis analyzed by twodimensional electrophoresis and immunoblotting. Electrophoresis. 1998;19:1511-1515.
19. Mostoslavsky G, Fischel R, Yachimovich N, et al. Lupus anti-DNA autoantibodies cross-react with a glomerular structural protein: a case for tissue injury by molecular mimicry. Eur J Immunol. 2001;31: 1221-1227.
20. Zykova SN, Seredkina N, Benjaminsen J, et al. Reduced fragmentation of apoptotic chromatin is associated with nephritis in lupus-prone (NZB x NZW)F(1) mice. Arthritis Rheum. 2008;58: 813-825.
21. Lee YH, Ji JD, Song GG. Fcgamma receptor IIB and IIIB polymorphisms and susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis. Lupus. 2009;18(8):727-734.
22. Bergtold A, Gavhane A, D'Agati V, et al. FcR-bearing myeloid cells are responsible for triggering murine lupus nephritis. J Immunol. 2006;177:7287-7295.
23. Li Y, Lee PY, Sobel ES, et al. Increased expression of FcγRI/CD64 on circulating monocytes parallels ongoing inflammation and nephritis in lupus. Arthritis Res Ther. 2009;11:R6.
24. Clynes R, Calvani N, Croker BP, et al. Modulation of immune response in pristane-induced lupus by expression of activation and inhibitory Fc receptors. Clin Exp Immunol. 2005;141:230-237.
25. Karp DR. Complement and systemic lupus erythematosus. Curr Opin Rheumatol. 2005;17:538-542.
26. Kavai M. Immune complex clearance by complement receptor type 1 in SLE. Autoimmun Rev. 2008;8:160-164.
27. Sinico RA, Ikehata M, Giammarresi G, et al. Anti-C1q autoantibodies in lupus nephritis: prevalence and clinical significance. Ann N Y Acad Sci. 2005;1050:193-200.
28. Trendelenburg M, Lopez-Trascasa M, Potlukova E, et al. High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. Nephrol Dial Transplant. 2006;21:3115-3121.
29. Trouw LA, Groeneveld TWL, Seelen MA, et al. Anti-C1q autoantibodies desposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J Clin Invest. 2004;114: 679-688.
30. Boule MW, Broughton C, Mackay F, et al. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatinimmunoglobulin G complexes. J Exp Med. 2004;199:1631-1640.
31. Kaveri SV, Mouthon L, Bayry J. Basophils and nephritis in lupus. N Engl J Med. 2010;363:1080-1082.
32. Cambridge G, Leandro MJ, Teodorescu M, et al. B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum. 2006;54: 3612-3622.
33. Furie R, Looney R, Rovin B, et al, editors. Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III LUNAR study. American College of Rheumatology National Meeting 2009; Philadelphia (PA). 2009 Oct 17-21. Abstract 1149.
34. Looney RJ. B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data. Drugs. 2010;70:529-540.
35. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 62:222-233.
36. Terrier B, Amoura Z, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum. 62:2458-2466.
37. Roche and Biogen Idec decide to suspend ocrelizumab treatment - rheumatoid arthritis development programme on hold. Biogen Idec, 2010. http://www.biogenidec.com/PRESS_RELEASE_DETAILS.aspx?ID=5981&ReqId=1400446. Accessed 2010 Oct 12.
38. Sanz I, Lee FE. B cells as therapeutic targets in SLE. Nat Rev Rheumatol. 2010;6:326-337.
39. Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Care Res. 2009;61:1168-1178.
40. Jacobi AM, Huang W, Wang T, et al. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2010;62:201-210.
41. Dorner T, Kaufmann J, Wegener WA, et al. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther. 2006;8:R74.
42. Dingli D, Rajkumar SV. How best to use new therapies in multiple myeloma. Blood Rev. 2010;24:91-100.
43. Neubert K, Meister S, Moser K, et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med. 2008;14:748-755.
44. Kang H-K, Michaels MA, Berner BR, et al. Very low-dose tolerance with nucleosomal peptides controls lupus and induces regulatory T cell subsets. J Immunol. 2005;174:3247-3255.
45. Cardiel MH, Tumlin JA, Furie RA, et al. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial. Arthritis Rheum. 2008;58:2470-2480.
46. Rand JH, Wu X-X, Quinn AS, et al. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-β2- glycoprotein I complexes to phospholipid bilayers. Blood. 2008;112: 1687-1695.
47. Toong C, Wienholt L, Adelstein S. Hydroxychloroquine reduces binding of anti-double stranded DNA antibodies in vitro. Intern Med J. 2010;40(Suppl 4):17.
48. McLachlan AJ, Cutler DJ, Tett SE. Plasma protein binding of the enantiomers of hydroxychloroquine and metabolites. Eur J Clin Pharmacol. 1993;44:481-484.
49. Scaria PV, Craig JC, Shafer RH. Differential binding of the enantiomers of chloroquine and quinacrine to polynucleotides: implications for stereoselective metabolism. Biopolymers. 1993;33:887-895.
50. Kwakye-Berko F, Meshnick S. Sequence preference of chloroquine binding to DNA and prevention of Z-DNA formation. Mol Biochem Paristol. 1990;39:275-278.
51. Fismen S, Mortensen ES, Rekvig OP. Nuclease deficiencies promote end-stage lupus nephritis but not nephritogenic autoimmunity in (NZBxNZW) F1 mice. Immunol Cell Biol. 2010 Jun 15.
52. Davis JC Jr, Manzi S, Yarboro C, et al. Recombinant human Dnase I (rhDNase) in patients with lupus nephritis. Lupus. 1999;8:68-76.
53. Mistry-Burchardi N, Schonermark U, Samtleben W. Apheresis in lupus nephritis. Ther Apher. 2001;5:161-170.
54. Yamaji K, Kim YJ, Tsuda H, et al. Long-term clinical outcomes of synchronized therapy with plasmapheresis and intravenous cyclophosphamide pulse therapy in the treatment of steroid-resistant lupus nephritis. Ther Apher Dial. 2008;12(4):298-305.
55. Danieli MG, Palmieri C, Salvi A, et al. Synchronised therapy and highdose cyclophosphamide in proliferative lupus nephritis. J Clin Apher. 2002;17:72-77.
56. Sugimoto K, Yamaji K, Yang KS, et al. Immunoadsorption plasmapheresis using a phenylalanine column as an effective treatment for lupus nephritis. Ther Apher Dial. 2006;10:187-192.
57. Takahashi S, Wada N, Harada K. Immunoadsorbent apheresis eliminates pathogenic IgG in childhood lupus nephritis. Pediatr Int. 2007;49:817-821.
58. Pascual V, Farkas L, Banchereau J. Systemic lupus erythematosus: all roads lead to type I interferons. Curr Opin Immunol. 2006;18: 676-682.
59. Lafyatis R, York M, Marshak-Rothstein A. Antimalarial agents: closing the gate on Toll-like receptors? Arthritis Rheum. 2006;54:3068-3070.
60. Fulmer T. Sparing steroids in lupus. SciBX. 2010;3:1-2.
61. Yao Y, Richman L, Higgs BW, et al. Neutralizaiton of interferon-α/β- inducible genes and downstream effect in a phase I trial of an antiinteferon-α monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum. 2009;60:1785-1796.
62. Madaio MP, Carlson J, Cataldo J, et al. Murine monoclonal anti-DNA antibodies bind directly to glomerular antigens and form immune deposits. J Immunol. 1987;138:2883-2889.
63. Chan TM, Leung JK, Ho SK, et al. Mesangial cell-binding anti-DNA antibodies in patients with systemic lupus erythematosus. J Am Soc Nephrol. 2002;13:1219-1229.
64. Du H, Chen M, Zhang Y, et al. Cross-reaction of anti-DNA autoantibodies with membrane proteins of human glomerular mesangial cells in sera from patients with lupus nephritis. Clin Exp Immunol. 2006;145:21-27.
65. Kramers C, Hylkema MN, van Bruggen MCJ, et al. Anti-nucleosome antibodies complexed to nucleosomal antigens show anti-DNA reactivity and bind to rat glomerular basement membrane in vivo. J Clin Invest. 1994;94:568-577.
66. Morioka T, Fujigaki Y, Batsford SR, et al. Anti-DNA antibody derived from a systemic lupus erythematosus (SLE) patient forms histone- DNA-anti-DNA complexes that bind to rat glomeruli in vivo. Clin Exp Immunol. 1996;104:92-96.
67. Tsao BP, Ohnishi K, Cheroutre H, et al. Failed self-tolerance and autoimmunity in IgG anti-DNA transgenic mice. J Immunol. 1992; 149:350-358.
68. Raz E, Brezis M, Rosenmann E, et al. Anti-DNA antibodies bind directly to renal antigens and induce kidney dysfunction in the isolated perfused rat kidney. J Immunol. 1989;142:3076-3082.
69. Ehrenstein MR, Katz DR, Griffiths MH, et al. Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice. Kidney Int. 1995;48:705-711.
70. Ravirajan CT, Rahman MA, Papadaki L, et al. Genetic, structural and functional properties of an IgG DNA-binding monoclonal antibody from a lupus patient with nephritis. Eur J Immunol. 1998;28:339-350.
71. Kalaaji M, Fenton KA, Mortensen ES, et al. Glomerular apoptotic nucleosomes are central target structures for nephritogenic antibodies in human SLE nephritis. Kidney Int. 2007;71:664-672.
72. Casals SP, Friou GJ, Myers LL. Significance of antibody to DNA in systemic lupus erythematosus. Arthritis Rheum. 1964;7:379-390.
73. Cervera R, Vinas O, Ramos-Casals M, et al. Anti-chromatin antibodies in systemic lupus erythematosus: a useful marker for lupus nephropathy. Ann Rheum Dis. 2003;62:431-434.
74. ter Borg EJ, Horst G, Hummel EJ, et al. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus: A long-term, prospective study. Arthritis Rheum. 1990;33(5):634-643.
75. Adler MK, Baumgarten A, Hecht B. Prognostic significance of DNA- binding capacity patterns in patients with lupus nephritis. Ann Rheum Dis. 1975;34:444-450.
76. Horowitz DM, Furie RA. Abetimus sodium: a medication for the prevention of lupus nephritis flares. Expert Opin Pharmacother. 2009;10: 1501-1507.
77. Donadio JVJ, Holley KE, Ferguson RH, et al. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N Engl J Med. 1978;299:1151-1155.
78. Houssiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002;46:2121-2131.
79. Houssiau FA, Vasconcelos C, D'Cruz D, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2010;69: 61-64.
80. Petri M, Brodsky RA, Jones RJ, et al. High-dose cyclophosphamide versus monthly intravenous cyclophosphamide for systemic lupus erythematosus: a prospective randomized trial. Arthritis Rheum. 2010; 62:1487-1493.
81. Yee CS, Gordon C, Dostal C, et al. EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis. Ann Rheum Dis. 2003;63: 525-529.
82. Illei GG, Yarboro CH, Kuroiwa T, et al. Long-term effects of combination treatment with fludarabine and low-dose pulse cyclophosphamide in patients with lupus nephritis. Rheumatology (Oxford). 2007;46: 952-956.
83. Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005;353:2219-2228.
84. Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20:1103-1112.
85. Radhakrishnan J, Moutzouris D-A, Ginzler EM, et al. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int. 2010;77:152-160.
86. Ong LM, Hooi LS, Lim TO, et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology. 2005;10:504-510.
87. Zhu B, Chen N, Lin Y, et al. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant. 2007;22: 1933-1942.
88. Lanata CM, Mahmood T, Fine DM, et al. Combination therapy of mycophenolate mofetil and tacrolimus in lupus nephritis. Lupus. 2010;19:935-940.
89. Grootscholten C, Ligtenberg G, Hagen EC, et al. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int. 2006;70: 732-742.
90. Grootscholten C, Bajema IM, Florquin S, et al. Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis. Arthritis Rheum. 2007;56:924-937.
91. Chan TM. Histologic deterioration and more flares: the case against azathioprine plus methylprednisolone in the treatment of proliferative lupus nephritis. Arthritis Rheum. 2007;56:702-704.
92. Zavada J, Pesickova S, Rysava R, et al. Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study. Lupus. 2010;19:1281-1289.
93. Ramos-Casals M, Soto MJ, Cuadrado MJ, et al. Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases. Lupus. 2009;18:767-776.
94. Li EK, Tam LS, Zhu TY, et al. Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis? Rheumatology (Oxford). 2009;48:892-898.
95. Lateef A, Lahiri M, Teng GG, et al. Use of rituximab in the treatment of refractory systemic lupus erythematosus: Singapore experience. Lupus. 2010;19:765-770.
96. Garcia-Carrasco M, Mendoza-Pinto C, Sandoval-Cruz M, et al. Anti- CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients. Lupus. 2010;19: 213-219.
97. Jonsdottir T, Gunnarsson I, Mourao AF, et al. Clinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion: pooled data from two cohorts. Rheumatology (Oxford). 2010;49:1502-1504.
98. Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med. 2004;350:971-980.
99. Contreras G, Tozman E, Nahar N, et al. Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide. Lupus. 2005;14:s33-s38.
100. Sahin GM, Sahin S, Kiziltas S, et al. Mycophenolate mofetil versus azathioprine in the maintenance therapy of lupus nephritis. Renal Failure. 2008;30:865-869.
101. Houssiau F, D'Cruz D, Sangle S, et al; the MAINTAIN Nephritis Trial Group. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis. 2010;69:2083-2089.
102. Wofsy D, Appel GB, Dooley MA, et al. Aspreva Lupus Management Study maintenance results. Lupus. 2010;19(Suppl):27 (CS12.6).
103. Moroni G, Doria A, Mosca M, et al. A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clin J Am Soc Nephrol. 2006;1:925-932.